Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
Trial details
- Registry ID
- NCT06641089
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponseNCT06641089 | MoonLake Immunotherapeutics AG | Phase 3 | Active not recruiting | 2027-01-04Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |